###begin article-title 0
###xml 15 21 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Prostaglandin F2alpha-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Abstract
###end title 2
###begin p 3
###xml 404 410 404 406 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 637 643 633 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 748 756 740 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 774 781 766 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 800 806 792 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1032 1038 1020 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1145 1151 1129 1131 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1550 1556 1530 1532 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 764 773 <span type="species:ncbi:10090">nude mice</span>
Pro-inflammatory mediators, like prostaglandin (PG) and chemokines, promote tumourigenesis by enhancing cell proliferation, migration of immune cells and recruitment of blood vessels. Recently we showed elevated expression of the chemokine (C-X-C motif) receptor 2 (CXCR2) in endometrial adenocarcinomas localized to neutrophils and neoplastic epithelial and vascular cells. Furthermore we found that PGF2alpha-F-prostanoid (FP) receptor regulates the expression of the CXCR2 ligand CXCL1, to promote neutrophil chemotaxis in endometrial adenocarcinomas. In the present study we identified another CXCR2 ligand, CXCL8 as a target for PGF2alpha-FP receptor signalling which enhances epithelial cell proliferation in endometrial adenocarcinoma cells in vitro and in nude mice in vivo. We found that PGF2alpha-FP receptor interaction induces CXCL8 expression in endometrial adenocarcinoma cells via the protein kinase C-calcium-calcineurin-NFAT signaling pathway. Promoter analysis revealed that CXCL8 transcriptional activation by PGF2alpha signaling is mediated by cooperative interactions between the AP1 and NFAT binding sites. Furthermore, PGF2alpha via the FP receptor induced the expression of the regulator of calcineurin 1 isoform 4 (RCAN1-4) via the calcineurin/NFAT pathway in a reciprocal manner to CXCL8. Using an adenovirus to overexpress RCAN1-4, we found that RCAN1-4 is a negative regulator of CXCL8 expression in endometrial adenocarcinoma cells. Taken together our data have elucidated the molecular and cellular mechanism whereby PGF2alpha regulates CXCL8 expression via the FP receptor in endometrial adenocarcinomas and have highlighted RCAN1-4 as a negative regulator of CXCL8 expression which may be exploited therapeutically to inhibit CXCL8-mediated tumour development.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 249 252 249 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">[2]</xref>
###xml 384 389 384 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib3" ref-type="bibr">[2,3]</xref>
###xml 407 412 407 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib4" ref-type="bibr">[2,4]</xref>
###xml 674 679 674 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5 bib6 bib7" ref-type="bibr">[5&#8211;7]</xref>
###xml 856 857 856 857 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 865 871 865 867 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 994 1000 990 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib9 bib10 bib11 bib12 bib13" ref-type="bibr">[8&#8211;13]</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human endometrium undergoes a state of inflammation and repair in a cyclical nature every 28 days [1]. This is characterized by the induction of inflammatory enzymes such as cyclooxygenase-2 (COX-2), release of prostaglandins (PG) and cytokines [2]. Chronic inflammation has been linked to increased cancer risk, for example hepatitis and colitis have been shown to promote liver [2,3] and colon cancer [2,4] respectively. By contrast, non-steroidal anti-inflammatory drug use and suppression of the COX-prostaglandin axis is associated with an inverse risk of developing cancer. In the Western world, endometrial cancer is one of the leading gynecological malignancies [5-7]. We and others have demonstrated elevated expression of the inflammatory enzyme COX-2, prostaglandin receptors and elevated signaling of the pro-inflammatory prostaglandins PGE2 and PGF2alpha and growth factors such as vascular endothelial growth factor and fibroblast growth factor in endometrial adenocarcinomas [8-13]. These findings suggest that endometrial cancers are controlled in an autocrine/paracrine manner by the COX-PG axis via the synthesis and release of potent growth factors.
###end p 6
###begin p 7
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr">[14]</xref>
###xml 368 369 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 385 389 385 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">[15]</xref>
###xml 533 539 533 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 603 607 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 748 752 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">[17]</xref>
###xml 784 788 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">[18]</xref>
###xml 819 823 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19" ref-type="bibr">[19]</xref>
Dysregulated chemoattractive cytokine (chemokine) expression is known to contribute to pathologies by promoting uncontrolled proliferation, invasion and migration of cells [14]. For example the chemokine C-X-C motif ligand 1 (CXCL1) and its G protein-coupled receptor CXCR2 has been demonstrated in regulating growth and development of colon carcinomas via the COX-PGE2 signaling axis [15]. Furthermore we have recently shown that CXCL1 expression is elevated in endometrial adenocarcinomas and promotes neutrophil chemotaxis via PGF2alpha-FP receptor signaling to extracellular signal-regulated kinase [16]. Another chemokine ligand of the CXCR2 receptor, CXCL8, has also been implicated in tumourigenesis by enhancing melanoma cell proliferation [17], alveolar epithelial neoplasia [18] and breast cancer development [19], however its expression and role in endometrial adenocarcinoma is unclear.
###end p 7
###begin p 8
###xml 44 50 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 119 127 115 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 264 270 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
Here we identified CXCL8 as a target for PGF2alpha-FP receptor signaling in endometrial adenocarcinoma cells. Using an in vitro model system, endometrial adenocarcinoma explants and a nude mouse xenograft model, we elucidated the molecular mechanisms mediating PGF2alpha-FP receptor signaling to CXCL8 in endometrial adenocarcinoma cells its potential role in endometrial tumourigenesis.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Reagents
###end title 10
###begin p 11
###xml 337 343 333 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 537 541 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 564 571 556 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21 bib22" ref-type="bibr">[21,22]</xref>
YM-254890 was kindly donated by Astellas Pharma Inc (Tsukuba, Japan). NFkappaB SN-50 inhibitory peptide was purchased from Biomol (Exeter, UK). Cyclosporin A and Inhibitor of NFAT-Calcineurin Association-6 (Inca-6), U73122, 4-cyano-3-methylisoquinoline (4C3MQ), SB225002 and RO-318220 were purchased from Calbiochem (Nottingham, UK). PGF2alpha, AL8810, transretinoic acid and EGTA were purchased from Sigma (Dorset, UK). The TAM-67 (dn cJun) was a kind gift from Dr Michael Birrer (National Cancer Institute, Maryland, USA) as described [20]. The CXCL8 constructs [21,22] were a kind gift from Dr Allan Brasier (Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas).
###end p 11
###begin title 12
Cell line, culture and treatments
###end title 12
###begin p 13
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">[10]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">[10]</xref>
###xml 399 407 399 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 466 472 466 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 532 539 528 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 554 560 550 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 600 606 592 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9 bib10" ref-type="bibr">[9,10]</xref>
###xml 896 900 888 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">[23]</xref>
###xml 969 976 961 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
###xml 1117 1124 1109 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24 bib25" ref-type="bibr">[24,25]</xref>
###xml 1160 1166 1152 1154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1535 1541 1523 1525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1545 1551 1529 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1623 1631 1603 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 89 94 <span type="species:ncbi:9606">human</span>
Wild type Ishikawa cells and Ishikawa cells engineered to stably express the full length human FP (PTGFR, accession no: ) receptor to the levels observed in endometrial adenocarcinomas, referred to as Ishikawa FPS cells, were cultured as described previously [10]. Ishikawa FPS cells were manufactured commercially, clonally selected and verified as described in our previous study [10]. Using this in vitro model system, we have previously demonstrated that the PGF2alpha-FP receptor signalling in Ishikawa FPS cells parallels the ex vivo effects of PGF2alpha on endometrial adenocarcinoma explants [9,10]. Transient transfections were performed using Superfect (Qiagen, Crawley, UK) as per the manufacturer's protocol. The concentrations of all chemical inhibitors and antibodies were determined empirically by titration using the manufacturer's guidelines as described in our previous studies [23]. A list of all chemical inhibitors and their targets is outlined in Table 1. Cell viability was determined for each inhibitor using the CellTitre 96 AQueous One Solution assay (Promega, Southampton, UK) as described [24,25]. Cells were treated with 100 nM PGF2alpha alone or in the presence of AL8810, YM254890, U73122 , 43CMQ, RO-318220, Cyclosporine A, Inca-6, EGTA, SN-50 for the time indicated. In parallel cells treated with vehicle (either distilled water, ethanol or dimethyl sulfoxide v/v) and chemical inhibitor served as a control for each treatment. Fold increase was calculated by dividing the values obtained from the PGF2alpha/PGF2alpha -inhibitor treatments by the vehicle/vehicle-inhibitor treatments. All in vitro cell culture experiments were carried out in duplicate.
###end p 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and tissue collection
###end title 14
###begin p 15
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 307 314 307 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10 bib24" ref-type="bibr">[10,24]</xref>
###xml 244 249 <span type="species:ncbi:9606">women</span>
Endometrial adenocarcinoma tissue (N = 30; 10 of each poorly, moderately and well differentiated adenocarcinoma) and normal endometrial tissue (N = 30; 10 of each proliferative, early secretory and mid secretory endometrium) were obtained from women undergoing hysterectomy as detailed in our prior studies [10,24]. Ethical approval was obtained from Lothian Research Ethics Committee and written informed consent was obtained from all subjects before tissue collection.
###end p 15
###begin title 16
Cytokine array
###end title 16
###begin p 17
###xml 225 231 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 241 244 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9" ref-type="bibr">[9]</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human cytokine antibody array I (RayBiotech, Inc., Norcross, GA) was used according to the manufacturer's instructions using conditioned medium collected from cultured Ishikawa FPS cells treated with vehicle or 100 nM PGF2alpha for 24 h [9]. The membranes were exposed to X-ray film and proteins quantified by densitometric analysis using the ImageQuant TL software (GE Healthcare, Little Chalfont, UK).
###end p 17
###begin title 18
Immunohistochemistry
###end title 18
###begin p 19
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 107 115 107 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib9 bib24" ref-type="bibr">[8,9,24]</xref>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 351 356 <span type="species:ncbi:10090">mouse</span>
Immunohistochemistry was performed on endometrial adenocarcinoma tissues or nude mouse xenografts (N = 20) [8,9,24] using the Vision Biosystems Bond Immunostaining Robot under normal operating conditions (Leica Microsystems Wetzlar, Germany). Immunostaining was performed following antigen retrieval using specific primary antibodies CXCL8 (1:200) or mouse monoclonal BrdU antibody (1:1000) or cytokeratin 18 antibody (1:500). Control tissue was incubated with immunoglobulin (IgG) from the host species (data not shown).
###end p 19
###begin title 20
Taqman quantitative RT-PCR
###end title 20
###begin p 21
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr">[24]</xref>
Quantitative RT-PCR was performed as detailed before [24] using sequence-specific primers and probes. Data were analyzed and processed using Sequence Detector v1.6.3 (Applied Biosystems). Expression of analyzed genes was normalised to RNA loading for each sample using the 18S ribosomal RNA or GAPDH as an internal standard. Results are expressed as fold increase above vehicle treated cells. Data are presented as mean +/- SEM.
###end p 21
###begin title 22
Secreted CXCL8 quantification
###end title 22
###begin p 23
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
Secreted CXCL8 was quantified using an in-house enzyme linked immunosorbent assay (ELISA) described previously [26]. A matched pair of capture and biotinylated labeled detection antibodies for CXCL8 and recombinant CXCL8 were used (R&D Systems, Oxford, UK). Data are presented as mean +/- SEM from at least 3 independent experiments.
###end p 23
###begin title 24
Luciferase reporter assay
###end title 24
###begin p 25
###xml 211 215 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
###xml 292 296 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">[22]</xref>
###xml 460 467 456 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10 bib23" ref-type="bibr">[10,23]</xref>
pNFkappaB-Luc and pAP1-Luc vectors were purchased from Clontech (Mountain View, CA). RCAN1-4 promoter reporter plasmids and pNFAT-Luc were kindly donated by Dr Takashi Minami (University of Tokyo, Tokyo, Japan) [27]. The CXCL8 promoter reporter constructs used have been previously described [22]. Cell transfection, stimulation and luciferase reporter assay was performed as described previously using the dual luciferase assay kit (Promega, Southampton, UK) [10,23]. Experiments were normalised for cell number and transfection efficiency by co-transfecting Ishikawa FPS cells with the appropriate firefly luciferase reporter together with the renilla luciferase reporter gene. Data are presented as mean +/- SEM from at least 3 independent experiments.
###end p 25
###begin title 26
Immunoblot analysis
###end title 26
###begin p 27
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 173 179 <span type="species:ncbi:9986">rabbit</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 433 437 <span type="species:ncbi:9925">goat</span>
###xml 443 449 <span type="species:ncbi:9986">rabbit</span>
###xml 490 494 <span type="species:ncbi:9925">goat</span>
###xml 500 505 <span type="species:ncbi:10090">mouse</span>
Western blot analysis on FPS cells was carried out as described previously [25]. After resolving and immunoblotting, membranes were incubated overnight at 4degreesC, with a rabbit anti RCAN-1-4 antibody (1:5000), a kind gift from Dr Erik W. Bush (Myogen, Inc, Westminster, CO), together with a mouse anti beta-actin antibody (1:800) (Santa Cruz Biotechnology, Santa Cruz, CA). The following day, cells were washed and incubated with goat anti-rabbit Alexafluor 680 (1:5000; Invitrogen) and goat anti-mouse IRDyetrade mark 800 (1:5000; Rockland, Gilbersville, PA) for 60 min at room temperature. Blots were visualized using an Odyssey infrared imaging system (LI-COR, Cambridge, UK).
###end p 27
###begin title 28
RCAN adenovirus infection
###end title 28
###begin p 29
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 374 380 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Ishikawa FPS cells were plated in 6 well plates at a density of 200,000 cells/well. After 24 h incubation, cells were washed with PBS and 1 ml of fresh medium containing 5 adenovirus molecules of infection (MOI or pfu)/plated) per cell was added to each well [25]. Cells were incubated for another 24 h and serum starved overnight before treatment with vehicle or 100 nM PGF2alpha. Adenovirus containing a scrambled sequence (CCGGCAAC AAGAT GAAGAGCACCAAC TCGAGTTGG TGCTC TTCATCTTG TTG TTTTT) was used as a control. Data are presented as mean +/- SEM from at least 3 independent experiments.
###end p 29
###begin title 30
Lentivirus shRNA gene silencing
###end title 30
###begin p 31
###xml 39 43 39 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 735 741 734 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
A short hairpin RNA (shRNA) lentivirus [25] was used to knock down the expression of RCAN1. Briefly, Ishikawa FPS cells were plated in 12 well plates at a density of 80,000 cells/well with either RCAN1 ShRNA lentivirus or lentivirus containing a scrambled sequence (CCGGCAAC AAGAT GAAGAGCA CCAAC TCGAGTTGG TGCTC TTCATCTTG TTG TTTTT). After 24 h incubation, cells were infected with virus-containing media at a 1:10 dilution of virus to target cell media and 0.6 mug/ml Polybrene to give an infection rate of 1 virus per cell (1 molecule of infection; MOI). The day after, medium was replaced with fresh serum-containing medium and 48 h post-infection, the cells which were serum starved overnight, were treated with vehicle or 1 nM PGF2alpha. Data are presented as mean +/- SEM from 3 independent experiments.
###end p 31
###begin title 32
Proliferation assay
###end title 32
###begin p 33
###xml 71 74 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
###xml 188 192 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24" ref-type="bibr">[24]</xref>
Proliferation of Ishikawa FPS cells was determined using a CellTitre 96(R)AQueous One Solution cell proliferation assay (Promega) as per the manufacturer's protocol as detailed previously [24]. Cells were treated with serum-free medium containing 5 mug/ml CXCL8 in the presence or absence of the CXCR2 antagonist SB225002 for 24, 48 or 72 h. Control wells received the same concentration of vehicle alone or vehicle and inhibitor. Following treatment, proliferation was measured by addition of the CellTitre 96(R)AQueous One Solution reagent as per the manufacturer's protocol. Data are presented as mean +/- SEM from 3 independent experiments.
###end p 33
###begin title 34
Xenograft tumour growth
###end title 34
###begin p 35
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nu</sup>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
A suspension of 5 x 106 Wild type Ishikawa or Ishikawa FPS cells in a total volume of 0.2 ml DMEM was injected subcutaneously into each dorsal flank of CD1-Foxn1nu mice (Charles River, UK). The mice (n = 30) were divided into two groups of equal tumour size after engraftment (1 week). The mice were injected twice weekly with 100 mug IgG or CXCL8 neutralising antibody (R&D systems, Abingdon, UK) via intra-peritoneal injection for 4 weeks. At the end of the study animals were injected with 50 mg/kg BrdU 2 h prior to culling. A proportion of the tumour was fixed in 0.2% paraformaldehyde for wax-embedding and immunohistochemistry. The animals were maintained under sterile conditions in individually vented cages. All animal care and experimental protocols were approved by the animal ethics committee of the University of Edinburgh and the Home Office of the United Kingdom government.
###end p 35
###begin title 36
BrdU/cytokeratin staining and quantification
###end title 36
###begin p 37
The expression of BrdU and cytokeratin in Ishikawa FPS IgG control and FPS CXCL8-neutralised tumours was determined by standard immunohistochemistry techniques as described above and quantified using standard stereology techniques. Briefly images were captured using a x 40 plan apo objective from a BH2 microscope (Olympus, Tokyo, Japan) fitted with an automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK) using a video camera (HV-C20; Hitachi, Tokyo, Japan) and were analyzed with Image-Pro Plus 4.5.1 software with a Stereology 5.0 plug-in (Media Cybernetics, Wokingham, Berkshire, UK). A total of 100 randomised fields of view were examined and counted from 8 tumours in each group. The total number of BrdU/cytokeratin positive epithelial cells per field of view were counted and expressed as a percentage of the total points per field of view and presented as mean +/- SEM.
###end p 37
###begin title 38
Statistical analysis
###end title 38
###begin p 39
The data in this study was analyzed by T-test or ANOVA using Prism 4.0c (Graph Pad, San Diego, CA).
###end p 39
###begin title 40
Results
###end title 40
###begin title 41
###xml 3 9 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
PGF2alpha-FP receptor activation induces CXCL8 expression and release in Ishikawa FPS cells
###end title 41
###begin p 42
###xml 99 105 99 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 165 171 161 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 361 367 357 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 402 406 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">[10]</xref>
###xml 494 500 486 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 503 504 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 521 527 513 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 530 531 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 554 560 546 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig. 1</xref>
###xml 563 564 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 625 631 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 762 768 750 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 771 772 759 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 811 817 799 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 820 821 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Using a chemokine protein array, we identified the inflammatory chemokine CXCL8 as a target for PGF2alpha-FP receptor signaling in endometrial adenocarcinoma cells (Fig. 1A). We subsequently investigated the regulation of CXCL8 via the F-prostanoid receptor in endometrial adenocarcinoma cells and the potential role of CXCL8 in endometrial adenocarcinomas. PGF2alpha stimulation of Ishikawa FPS cells [10] resulted in a significant time-dependent increase in the expression of CXCL8 promoter (Fig. 1B; P < 0.001), mRNA (Fig. 1C; P < 0.001) and protein (Fig. 1D; P < 0.001). Co-treatment of Ishikawa FPS cells with 100 nM PGF2alpha and AL8810, YM254890, U73122, RO-318220, EGTA, Inca-6 or CsA, but not 4C3MQ significantly inhibited the expression of CXCL8 mRNA (Fig. 2A; P < 0.05) and release of CXCL8 protein (Fig. 2B; P < 0.001).
###end p 42
###begin title 43
###xml 3 9 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
PGF2alpha induces activation of CXCL8 promoter through AP1 and NFAT
###end title 43
###begin p 44
###xml 107 113 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 377 384 373 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21 bib22" ref-type="bibr">[21,22]</xref>
###xml 549 555 545 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 558 559 554 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 708 714 704 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 717 718 713 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1022 1028 1018 1020 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1030 1036 1022 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1039 1040 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1132 1138 1124 1126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1217 1223 1205 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1226 1227 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1486 1492 1461 1463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1494 1500 1465 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1503 1504 1474 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1626 1632 1593 1595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1923 1929 1882 1884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1931 1937 1886 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1940 1941 1895 1896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1976 1982 1931 1933 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 2207 2213 2150 2156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 2216 2217 2159 2160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
To determine the regions of the CXCL8 promoter involved in regulating gene transcription in response to PGF2alpha-FP receptor interaction, Ishikawa FPS cells were transiently transfected with plasmid cDNA containing the full length (- 1400/+ 44) or serial deletions of the CXCL8 promoter (- 162/+ 44, - 132/+ 44, - 99/+ 44 and - 54/+ 44) linked to the luciferase reporter gene [21,22]. We found a considerable reduction in promoter activity when the CXCL8 promoter was truncated down to - 99 nucleotides of the 5' flanking region of the CXCL8 gene (Fig. 2C; P < 0.01). No further reduction in promoter activity was observed in the - 54 nucleotides truncated construct which only contains the CXCL8 TATA box (Fig. 2C; P < 0.01). The use of site directed mutated versions of the - 162 CXCL8 promoter-luciferase construct at consensus binding sequences for activator protein 1 (AP1) and nuclear factor of activated T-cells (NFAT) showed that these binding sites are required for the induction of transcription of CXCL8 by PGF2alpha (Fig. 2C, P < 0.01). Furthermore, we confirmed that CXCL8 transcriptional activation in response to PGF2alpha-FP receptor signalling occurred via the PKC-calcium-calcineurin-NFAT pathway (Fig. 2D, P < 0.01) and this was independent of nuclear factor (NF)kappaB (as NFAT and NFkappaB have similar consensus motifs on the DNA binding domain) since the NFkappaB inhibitory peptide SN-50 (100 mug/ml) did not reduce the activity of CXCL8 promoter induced by PGF2alpha (Fig. 2D, P < 0.01). In agreement with this, Ishikawa FPS cells transfected with the pNFkappaB-Luc vector and treated with 100 nM PGF2alpha did not induce NFkappaB-driven luciferase activity, whereas transfection of Ishikawa FPS cells with the pNFAT-Luc or pAP1-Luc vector which contains the a cis-acting NFAT or AP1 enhancer element showed a time dependent increase in luciferase activity in response to treatment with 100 nM PGF2alpha (Fig. 2E, P < 0.01). We confirmed that the PGF2alpha-mediated activation of the - 162/+ 44 CXCL8 reporter gene construct occurred via the NFAT and AP1, but not NFkappaB, elements using specific inhibitors of NFAT (Inca-6) and AP1 (transretinoic acid; RA) and NFkappaB (SN-50) (Fig. 2F, P < 0.01).
###end p 44
###begin title 45
###xml 58 64 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
NFAT and AP1 cis-enhancer elements are co-regulated by PGF2alpha
###end title 45
###begin p 46
###xml 129 136 129 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28 bib29 bib30" ref-type="bibr">[28&#8211;30]</xref>
###xml 185 191 185 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 321 327 317 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 330 331 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 354 360 350 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 363 364 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 458 464 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 726 730 718 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">[31]</xref>
###xml 929 933 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">[20]</xref>
###xml 986 992 978 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 995 996 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1015 1021 1007 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1024 1025 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1239 1245 1231 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1248 1249 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1300 1306 1292 1294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
NFAT complexes with the two AP1 subunits, cJun and cFos via direct protein-protein interactions to co-ordinate promoter activity [28-30]. Treatment of Ishikawa FPS cells with 100 nM PGF2alpha and AL8810, YM254890, U73122, RO-318220, EGTA, Inca-6 or CsA, but not 4C3MQ significantly inhibited the activation of pNFAT-Luc (Fig. 3A; P < 0.01) and pAP1-Luc (Fig. 3B; P < 0.01) luciferase. Since these transcriptional regulatory proteins are both regulated by PGF2alpha via the PKC-calcium-calcineurin-NFAT pathways and are essential for CXCL8 activity, we performed further studies to determine whether the CXCL8 promoter was co-operatively regulated by the NFAT-AP1 complex as has been described for other cytokines such as IL-2 [31]. We found that transretinoic acid (which causes dissociation of the AP1 complex) or co-transfection of Ishikawa FPS cells with the dn c-Jun (also called TAM67) that lacks the transactivating domain [20] abolished both the transcriptional activity of AP1 (Fig. 3C, P < 0.01) and NFAT (Fig. 3D; P < 0.01) promoter elements. Furthermore, disruption of the AP1 protein complex with the dn c-Jun construct abolished the transcriptional activity of the truncated - 162/+ 44 as well as the full length - 1400/+ 44 (Fig. 3E; P < 0.01) CXCL8 promoter activity in response to PGF2alpha treatment indicating that an AP1-NFAT protein complex is essential for CXCL8 activation.
###end p 46
###begin title 47
###xml 3 9 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
PGF2alpha-FP receptor activation induces the expression of the calcineurin negative modulator RCAN1
###end title 47
###begin p 48
###xml 30 36 30 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 354 358 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr">[32]</xref>
###xml 382 388 378 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 435 441 427 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 521 527 513 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 530 531 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 710 716 702 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 719 720 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 759 765 751 753 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Having identified that the PGF2alpha-FP receptor activation of CXCL8 was mediated via the calcineurin-NFAT signalling pathway, we explored whether CXCL8 was regulated by the regulator of calcineurin 1 (RCAN1), previously known as Down syndrome critical region gene 1 (DSCR1) or Adapt 78 which is known to endogenously modulate calcineurin-NFAT signaling [32]. We identified that PGF2alpha induces the expression of isoform 4 of RCAN1 (Fig. 4A) in rapid time-dependent manner, with maximal levels of expression after 4 h (Fig. 4B; P < 0.001). Co-treatment of Ishikawa FPS cells with AL8810, YM254890. U73122, RO-318220, EGTA, Inca-6 or CsA, but not 4C3MQ significantly inhibited the expression of RCAN1-4 mRNA (Fig. 4C; P < 0.001). These data indicate that PGF2alpha-FP receptor signalling regulates RCAN1-4 expression in a reciprocal time dependent manner to CXCL8 via the same calcium-calcineurin-NFAT signal transduction pathway regulating CXCL8.
###end p 48
###begin title 49
###xml 35 41 35 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
RCAN1-4 overexpression inhibits PGF2alpha-induced expression of CXCL8
###end title 49
###begin p 50
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
###xml 145 151 145 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 227 233 227 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 497 503 493 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 524 530 520 522 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 569 575 561 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 578 579 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 601 607 593 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 610 611 602 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
RCAN1-4 is known to bind to calcineurin and inhibit activation of NFAT when overexpressed [33]. Overexpression of RCAN1-4 in Ishikawa FPS cells (Fig. 4D, E and F; P < 0.01) using RCAN1-4 adenovirus significantly reduced the PGF2alpha-FP receptor induction of CXCL8 promoter and mRNA expression and protein secretion compared to cells infected with the scrambled control virus. Conversely, infection of cells with RCAN1-4 lentivirus short hairpin (Sh) RNA which ablates RCAN1-4 protein expression (Fig. 5A), augmented the PGF2alpha-FP receptor activation of CXCL8 mRNA (Fig. 5B; P < 0.01) and protein (Fig. 5C; P < 0.01) confirming that RCAN1-4 is a negative regulator of CXCL8.
###end p 50
###begin p 51
###xml 274 280 274 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 370 376 370 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 379 380 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
We further investigated the effect of disruption of NFAT activity by RCAN1-4 overexpression on activation of the NFAT and AP1 DNA transactivation domains. We found that as observed for the disruption of the AP1 transcription complex with the transretinoic acid or dn c-Jun (Fig. 3C), inhibiting NFAT activity with the RCAN1-4 adenovirus also inhibited the AP1 and NFAT (Fig. 5D; P < 0.01) promoter activity, giving further support for co-operativity between AP1 and NFAT.
###end p 51
###begin title 52
###xml 47 55 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
CXCL8 enhances Ishikawa FPS cell proliferation in vitro
###end title 52
###begin p 53
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 259 265 259 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 438 444 438 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
CXCL8 has recently been shown to enhance the proliferation and migration of squamous carcinoma cells [34]. We treated Ishikawa FPS cells in vitro with CXCL8 peptide and found significantly augmented cellular proliferation compared with vehicle treated cells (Fig. 5E; P < 0.01). Co-treatment of cells with CXCL8 and the CXCR2 antagonist SB225002 abolished the CXCL8-induced increase in cell proliferation at all time points investigated (Fig. 5E; P < 0.01).
###end p 53
###begin title 54
CXCL8 expression in endometrial adenocarcinoma and normal endometrium
###end title 54
###begin p 55
###xml 137 143 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 172 178 168 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 333 334 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 579 585 575 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
We next explored the expression of CXCL8 in endometrial adenocarcinoma and normal endometrial tissues and its potential regulation by PGF2alpha via the FP receptor. CXCL8 (Fig. 6A) mRNA expression was significantly up-regulated in endometrial adenocarcinoma irrespective of grade or stage of cancer compared with normal endometrium (P < 0.001). CXCL8 immunoreactivity in endometrial adenocarcinomas was observed in the glandular epithelium (G; as indicated by the brown staining) with some diffuse stromal (S), staining irrespective of grade/stage of endometrial adenocarcinoma (Fig. 6B).
###end p 55
###begin p 56
###xml 3 9 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 129 135 125 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 170 176 166 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 284 285 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 359 365 355 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 368 369 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 433 439 429 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 563 571 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
PGF2alpha stimulation of endometrial adenocarcinoma explants resulted in a significant increase in the expression of CXCL8 mRNA (Fig. 6C) and secretion of CXCL8 protein (Fig. 6D), which was inhibited by co-treatment of tissue explants with the specific FP receptor antagonist AL8810 (P < 0.001). Furthermore, infection of endometrial adenocarcinoma explants (Fig. 6E; P < 0.001) using RCAN1-4 adenovirus significantly reduced the PGF2alpha-FP receptor induction of CXCL8 mRNA expression compared to tissue infected with the scrambled control virus similar to our in vitro data using Ishikawa FPS cells.
###end p 56
###begin title 57
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 50 59 <span type="species:ncbi:10090">nude mice</span>
CXCL8 enhances Ishikawa FPS cell proliferation in nude mice in vivo
###end title 57
###begin p 58
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 460 466 460 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 507 514 503 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 864 870 860 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 873 874 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1178 1184 1174 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 1193 1194 1189 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1576 1582 1572 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 189 198 <span type="species:ncbi:10090">nude mice</span>
###xml 200 204 <span type="species:ncbi:10090">Mice</span>
###xml 470 479 <span type="species:ncbi:10090">nude mice</span>
###xml 730 735 <span type="species:ncbi:10090">mouse</span>
To explore whether CXCL8 induced by FP receptor signalling could alter tumour growth in vivo we injected wild type Ishikawa (WT) cells or FPS cells subcutaneously into the dorsal flanks of nude mice. Mice were then regularly injected with control IgG (WT and FPS xenografts) or CXCL8 antibody (FPS xenografts). Tumours formed from FPS cells expressed significantly higher CXCL8 mRNA as compared to WT tumours indicating that there was sufficient endogenous PGF2alpha in nude mice to induce CXCL8 expression in vivo via the FP receptor similar to our observations in these cell lines vitro (data not shown). Immunohistochemical staining showed a significant reduction in the BrdU incorporation in the epithelial compartment of the mouse tumours in the animals engrafted with FPS tumour and treated with a CXCL8 neutralising antibody compared with FPS IgG controls (Fig. 7A; P < 0.001). In addition, we found that the administration of the CXCL8 neutralising antibody to FPS xenografts had reduced the amount of cytokeratin 18 positive immunoreactivity (as indicated by the brown staining) thereby confirming a reduction in the epithelial cell component of the xenograft tumours (Fig. 7B and C, P < 0.001). However, we observed no significant reduction in tumour size or volume between the various treatment groups during the 4 weeks of neutralising antibody administration, but rather a gross infiltration of other cell types (stromal, vascular, immune cells as indicated by the blue haematoxylin counterstain) to maintain tumour volume as shown in the representative image in Fig. 7B.
###end p 58
###begin title 59
Discussion
###end title 59
###begin p 60
###xml 93 100 93 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib35" ref-type="bibr">[2, 35]</xref>
###xml 130 136 130 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 259 266 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17 bib18 bib19" ref-type="bibr">[17&#8211;19]</xref>
Inflammation and infection are estimated to contribute to 25% of all cancer cases world wide [2, 35]. Here we demonstrate that PGF2alpha-FP receptor signalling can promote the expression of a potent chemokine with known tumourigenic and angiogenic properties [17-19].
###end p 60
###begin p 61
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">[15]</xref>
###xml 155 158 155 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">[2]</xref>
###xml 245 255 245 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14 bib36 bib37 bib38" ref-type="bibr">[14,36&#8211;38]</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 459 465 459 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 694 698 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">[21]</xref>
###xml 812 818 808 810 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1292 1296 1280 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib39" ref-type="bibr">[39]</xref>
###xml 1456 1463 1444 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28 bib29 bib30" ref-type="bibr">[28&#8211;30]</xref>
###xml 1583 1589 1571 1573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1683 1689 1667 1669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Chemokines have emerged as important regulators of tumour function in colorectal carcinomas [15], melanomas, pancreatic, head and neck and lung carcinomas [2], and are known to promote angiogenesis and proliferation of endometrial stromal cells [14,36-38]. Moreover we have recently shown that chemokines regulated by the FP receptor can also induce neutrophil chemotaxis in endometrial adenocarcinomas [16]. In the present study we have demonstrated that PGF2alpha promotes the synthesis and release of CXCL8 in a time-dependent manner via the protein kinase C-calcium-calcineurin-NFAT signalling pathway. Using luciferase reporter gene analysis and site directed mutations of the AP1 or NFAT [21] binding site on the CXCL8 promoter we determined that both AP1 and NFAT were essential for gene activation by PGF2alpha and that this was independent of NFkappaB. Moreover we determined that both AP1- and NFAT cis-acting enhancer elements were regulated by the same protein kinase C-calcium-calcineurin-NFAT pathway which regulates CXCL8 activation. NFAT and AP1 are known to co-operate and mutually stabilise each others interaction with the DNA binding domain to allow full gene transactivation to occur, and this interaction is critical for transcription of cytokines such as interleukin-2 [39]. Furthermore, NFAT has been shown to complex with the two AP1 subunits, cJun and cFos via direct protein-protein interactions to co-ordinate promoter activity [28-30]. We found that disruption of the AP1 complex with dn c-Jun or transretinoic acid, abolished not only the ability of PGF2alpha to mediate transactivation of the AP1 cis-acting enhancer element, but also abolished the PGF2alpha -mediated transactivation of the NFAT luciferase reporter gene as well as the - 162 and full length - 1400 CXCL8 luciferase reporter gene. These data give further support to the co-ordinated regulation of CXCL8 transcription by a protein complex comprising of the AP1 proteins and NFAT.
###end p 61
###begin p 62
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr">[32]</xref>
###xml 338 346 338 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27 bib33" ref-type="bibr">[27, 33]</xref>
###xml 391 397 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 652 656 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
###xml 773 777 769 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib25" ref-type="bibr">[25]</xref>
###xml 882 888 878 880 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 950 956 942 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
NFAT activation by calcineurin, which mediates its dephosphorylation and translocation to the nucleus is known to be regulated by the regulator of calcinerin (RCAN) [32]. RCAN1-4 is known to bind to calcineurin and previous studies have shown that overexpression of this protein results in an inhibition of calcineurin activation of NFAT [27, 33]. We showed that RCAN1-4 was regulated by PGF2alpha in a reciprocal time-dependent manner to that of CXCL8, with a peak that preceded CXCL8 by 8 h, via the calcium-calcineurin-NFAT pathway. This is in agreement with other published observations that show that expression of this isoform is induced by NFAT [27] and can negatively regulate prokineticin-prokineticin receptor 1 signaling to CXCL8 in endometrial epithelial cells [25]. Moreover adenovirus and lentivirus infection studies showed that RCAN1-4 is a negative regulator of PGF2alpha-FP receptor mediated induction of CXCL8 by inhibiting the PGF2alpha- mediated activation of the AP1 and NFAT cis-acting enhancer elements, similar to our observations for the dn c-Jun and transretinoic acid, giving further support for the co-operativity of NFAT and AP1 in mediating the full transcriptional activation of CXCL8.
###end p 62
###begin p 63
###xml 142 149 142 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40" ref-type="bibr">[40]</xref>
###xml 250 258 250 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
We investigated the effect of CXCL8 on cellular proliferation since humanised CXCL8 antibody has recently been shown to inhibit tumour growth in vivo[40]. We found that CXCL8 could enhance epithelial cell proliferation via interaction with the CXCR2 in vitro.
###end p 63
###begin p 64
###xml 24 30 24 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 506 510 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">[36]</xref>
###xml 683 687 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 773 780 769 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 787 793 783 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1030 1036 1022 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1202 1210 1190 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1478 1486 1466 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14 bib38" ref-type="bibr">[14, 38]</xref>
###xml 1602 1606 1590 1594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 1727 1731 1715 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib41" ref-type="bibr">[41]</xref>
To determine whether PGF2alpha-FP receptor signaling regulates CXCL8 in endometrial adenocarcinomas, we determined the expression pattern and localization of CXCL8 in endometrial adenocarcinoma tissue. We found that CXCL8 mRNA expression was elevated in endometrial adenocarcinomas irrespective of grade or stage and localized to the neoplastic glandular epithelial compartment with some diffuse stromal staining-similar to expression reported for this chemokine in normal endometrial glandular epithelium [36]. Furthermore we have shown that CXCL8 immunolocalised to the same cellular compartment in endometrial adenocarcinomas as the FP receptor and CXCR2 (the receptor for CXCL8) [16] and that CXCL8 expression and release is regulated in endometrial carcinoma explants ex vivo by PGF2alpha via the FP receptor. Moreover we have shown that CXCL8 expression in endometrial adenocarcinoma explants is negatively regulated by RCAN1-4 since infection of endometrial adenocarcinoma explants with RCAN1-4 adenovirus abolished the PGF2alpha-FP receptor-mediated induction of CXCL8. These data suggest that the molecular mechanism that we have elucidated for the regulation of CXCL8 via the RCAN1-4 pathway in vitro can potentially regulate CXCL8 in endometrial adenocarcinomas. Although little is known of the role of CXCL8 in endometrial cancer, dysregulated CXCL8 and CXCR2 expression has recently been proposed to play a role in other endometrial disorders such as endometriosis [14, 38]. Furthermore, CXCL8 has recently been shown to enhance the proliferation and migration of squamous carcinoma cells [34] and its elevated secretion in esophageal squamous cell carcinomas has been related to lymph node and distant metastases [41].
###end p 64
###begin p 65
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 343 349 343 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 349 356 345 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 432 438 428 430 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 438 446 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 522 529 514 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 99 108 <span type="species:ncbi:10090">nude mice</span>
###xml 573 582 <span type="species:ncbi:10090">nude mice</span>
Finally we investigated the impact of CXCL8 expression on tumour development in vivo by engrafting nude mice with wild type Ishikawa cells and FPS Ishikawa cells. We found that CXCL8 expression was significantly elevated in FPS xenograft tumours compared with wild type tumours indicating that FP receptor was being activated by endogenous PGF2alphain vivo similar to our observations using FPS cells and administering exogenous PGF2alphain vitro. We further confirmed that CXCL8 played a role in epithelial cell function in vivo, as Ishikawa FPS cell tumour xenografts in nude mice treated with a CXCL8 neutralising antibody displayed reduced neoplastic epithelial cell proliferation characterised by reduced BrdU incorporation and reduced cytokeratin 18 immunoreactivity, compared to IgG treated controls. Further studies are currently underway in our laboratory to determine whether alterations in cell type and density within a tumour effects tumour outcome.
###end p 65
###begin p 66
###xml 43 49 43 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 64 70 64 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 551 559 547 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 564 571 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 681 687 677 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Taken together, our data (as summarised in Fig. 8) show that PGF2alpha-FP receptor activation in endometrial adenocarcinoma cells promotes the activation of RCAN1-4 and CXCL8 via the Gq-PLC-PKC-calcium-calcineurin-NFAT. The activation of RCAN1-4 is reciprocal to CXCL8, such that at the peak of RCAN1-4 expression, CXCL8 expression is minimal and vice versa. As RCAN1-4 expression reduces over time, the expression of CXCL8 increases to promote tumour cell proliferation. Furthermore, we confirmed that RCAN1-4 is a potent negative regulator of CXCL8 in vitro and ex vivo in endometrial adenocarcinomas explants and that the regulation of transcriptional activation of CXCL8 by PGF2alpha occurs via the co-operativity between AP1 and NFAT DNA binding elements. To our knowledge this represents the first report mapping the molecular and cellular regulation of CXCL8 by prostanoids and its potential involvement in endometrial cancers.
###end p 66
###begin title 67
Acknowledgments
###end title 67
###begin p 68
###xml 59 66 <span type="species:ncbi:9606">patient</span>
The authors thank Anne Saunderson and Sharon McPherson for patient recruitment, consent and sample collection.
###end p 68
###begin p 69
This study was supported by MRC core funding to HNJ (U.1276.00.004.00002.01).
###end p 69
###begin title 70
References
###end title 70
###begin article-title 71
Prostaglandins and menstruation
###end article-title 71
###begin article-title 72
Inflammation and cancer
###end article-title 72
###begin article-title 73
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus and hepatocellular carcinoma
###end article-title 73
###begin article-title 74
###xml 15 23 <span type="species:ncbi:9606">patients</span>
Cancer risk in patients with inflammatory bowel disease
###end article-title 74
###begin article-title 75
Ovarian and endometrial cancers
###end article-title 75
###begin article-title 76
Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings
###end article-title 76
###begin article-title 77
The epidemiology of endometrial cancer
###end article-title 77
###begin article-title 78
Expression of COX-2 and PGE synthase and synthesis of PGE2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors
###end article-title 78
###begin article-title 79
F-prostanoid receptor regulation of fibroblast growth factor 2 signalling in endometrial adenocarcinoma cells
###end article-title 79
###begin article-title 80
###xml 77 82 <span type="species:ncbi:9606">human</span>
A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas
###end article-title 80
###begin article-title 81
###xml 100 105 <span type="species:ncbi:9606">human</span>
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-{delta} in human endometrial adenocarcinoma
###end article-title 81
###begin article-title 82
###xml 50 55 <span type="species:ncbi:9606">human</span>
Prostaglandin receptor signalling and function in human endometrial pathology
###end article-title 82
###begin article-title 83
Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium
###end article-title 83
###begin article-title 84
Uterine chemokines in reproductive physiology and pathology
###end article-title 84
###begin article-title 85
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer
###end article-title 85
###begin article-title 86
Prostaglandin F2{alpha}-F-prostanoid receptor signaling promotes neutrophil chemotaxis via chemokine (C-X-C motif) ligand 1 in endometrial adenocarcinoma
###end article-title 86
###begin article-title 87
Purification of melanoma growth stimulatory activity
###end article-title 87
###begin article-title 88
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras
###end article-title 88
###begin article-title 89
CXC chemokines located in the 4q21 region are up-regulated in breast cancer
###end article-title 89
###begin article-title 90
AP-1 blockade inhibits the growth of normal and malignant breast cells
###end article-title 90
###begin article-title 91
###xml 91 110 <span type="species:ncbi:210">Helicobacter pylori</span>
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection
###end article-title 91
###begin article-title 92
###xml 52 79 <span type="species:ncbi:12814">respiratory syncytial virus</span>
Requirement of a novel upstream response element in respiratory syncytial virus-induced IL-8 gene expression
###end article-title 92
###begin article-title 93
Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element
###end article-title 93
###begin article-title 94
###xml 78 83 <span type="species:ncbi:9606">human</span>
Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways
###end article-title 94
###begin article-title 95
Prokineticin 1 modulates IL-8 expression via the calcineurin/NFAT signaling pathway
###end article-title 95
###begin article-title 96
Differential concentrations of monocyte chemotactic protein-1 and interleukin-8 within the fluid compartments present during the first trimester of pregnancy
###end article-title 96
###begin article-title 97
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis
###end article-title 97
###begin article-title 98
The leucine zipper domain controls the orientation of AP-1 in the NFAT.AP-1.DNA complex
###end article-title 98
###begin article-title 99
Control of the orientation of Fos-Jun binding and the transcriptional cooperativity of Fos-Jun-NFAT1 complexes
###end article-title 99
###begin article-title 100
Dynamics of Fos-Jun-NFAT1 complexes
###end article-title 100
###begin article-title 101
Partners in transcription: NFAT and AP-1
###end article-title 101
###begin article-title 102
Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin
###end article-title 102
###begin article-title 103
Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo
###end article-title 103
###begin article-title 104
Roles of CXCL8 in squamous cell carcinoma proliferation and migration
###end article-title 104
###begin article-title 105
Inflammation and cancer: an ancient link with novel potentials
###end article-title 105
###begin article-title 106
###xml 21 26 <span type="species:ncbi:9606">human</span>
Interleukin-8 in the human endometrium
###end article-title 106
###begin article-title 107
Interleukin-8 induces proliferation of endometrial stromal cells: a potential autocrine growth factor
###end article-title 107
###begin article-title 108
Expression of interleukin-8 receptors in endometriosis
###end article-title 108
###begin article-title 109
Dual role of the nuclear factor of activated T cells insert region in DNA recognition and cooperative contacts to activator protein 1
###end article-title 109
###begin article-title 110
###xml 121 126 <span type="species:ncbi:9606">human</span>
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma
###end article-title 110
###begin article-title 111
###xml 172 179 <span type="species:ncbi:9606">patient</span>
Elevation of circulating interleukin-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas-implication for clinical evaluation of cancer patient
###end article-title 111
###begin article-title 112
AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor
###end article-title 112
###begin article-title 113
Galphaq/11-selective inhibitor
###end article-title 113
###begin article-title 114
###xml 91 109 <span type="species:ncbi:306190">Chromobacterium sp</span>
YM-254890 analogues, novel cyclic depsipeptides with Galpha(q/11) inhibitory activity from Chromobacterium sp. QS3666
###end article-title 114
###begin article-title 115
###xml 80 85 <span type="species:ncbi:9606">human</span>
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils
###end article-title 115
###begin article-title 116
Selective inhibition of cyclic AMP-dependent protein kinase by isoquinoline derivatives
###end article-title 116
###begin article-title 117
The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase
###end article-title 117
###begin article-title 118
Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules
###end article-title 118
###begin article-title 119
Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoetic cells
###end article-title 119
###begin article-title 120
Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence
###end article-title 120
###begin article-title 121
Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization
###end article-title 121
###begin article-title 122
Ca2+-induced inhibition of the cardiac Ca2+ channel depends on calmodulin
###end article-title 122
###begin article-title 123
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration
###end article-title 123
###begin p 124
###xml 23 29 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 101 107 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 227 233 219 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 470 476 458 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 696 702 680 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 842 848 822 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 888 889 864 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 297 302 <span type="species:ncbi:9606">human</span>
CXCL8 is induced by PGF2alpha-FP receptor signalling. (A) Chemokine release in response to 100 nM PGF2alpha treatment in Ishikawa FPS cells. Conditioned medium obtained from Ishikawa FPS cells treated with vehicle or 100 nM PGF2alpha for 24 h was tested for the expression of chemokines using the human cytokine antibody array (RayBiotech). (B) FPS cells were transiently transfected with the full length - 1400/+ 44 CXCL8 promoter and treated with vehicle or 100 nM PGF2alpha for 4, 6, 8 and 24 h. CXCL8 promoter activity was determined by luciferase reporter assay. (C) CXCL8 mRNA expression in Ishikawa FPS cells following treatment of cells for 2, 4, 6, 8, 12, 24, 48 and 72 h with 100 nM PGF2alpha. (D) CXCL8 protein secretion in Ishikawa FPS cells following treatment of cells for 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 h with 100 nM PGF2alpha. (b is significantly different from a; P < 0.01). Data are represented as mean +/- SEM.
###end p 124
###begin p 125
###xml 3 9 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 206 212 202 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 224 230 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 810 816 791 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1040 1046 1017 1019 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1369 1375 1338 1340 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1532 1538 1497 1499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1650 1651 1611 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PGF2alpha-FP receptor-mediated CXCL8 is regulated via the calcium-calcineurin-NFAT pathway. (A) CXCL8 mRNA expression and (B) protein secretion in Ishikawa FPS cells treated for 8 h with vehicle, 100 nM PGF2alpha, 100 nM PGF2alpha in the absence/presence of AL8810 (50 muM), YM254890 (1 muM), U73122 (10 muM), 4C3MQ (1 muM), RO-318220 (1 muM ), EGTA (1.5 mM), Inca-6 (40 muM) or CsA (1 muM) as determined by quantitative RT-PCR analysis and ELISA respectively. (C) CXCL8 luciferase activity in Ishikawa FPS cells transiently transfected with the full length (- 1400/+ 44) or sequential 5' deletions (- 162/+ 44, - 132/+ 44, - 66/+ 44, - 54/+ 44) of the CXCL8 promoter or the - 162/+ 44 construct containing site-directed mutations in the NFAT or AP1 binding sites. Cells were treated with vehicle or 100 nM PGF2alpha for 8 h and expressed as fold above the - 54/+ 44 construct which contains only the TATA box. (D) FPS cells were transiently transfected with the full length - 1400/+ 44 CXCL8 promoter and treated with vehicle or 100 nM PGF2alpha for 8 h in the absence/presence of AL8810, YM254890, EGTA, CsA, Inca-6 or SN-50. CXCL8 promoter activity was determined by luciferase reporter assay. (E) FPS cells were transiently transfected with pAP1-luc, pNFAT-luc or pNF NFkappaB -luc reporter cDNA constructs and treated for 2, 4, 8 or 24 h with vehicle or 100 nM PGF2alpha. (F) CXCL8 luciferase activity in FPS cells transfected with the - 162/+ 44 CXCL8 luciferase reporter plasmid. Cells were treated with vehicle or 100 nM PGF2alpha for 8 h in absence/presence of Inca-6, SN-50 or transretinoic acid (RA). (b is significantly different from a; P < 0.05). Data are represented as mean +/- SEM.
###end p 125
###begin p 126
###xml 233 239 233 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 251 257 247 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 858 864 850 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 958 959 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The AP1 protein c-Jun activates the AP1 and NFAT cis-acting enhancer elements to transactivate the CXCL8 promoter. FPS cells were transiently transfected with pNFAT-luc (A) or pAP1-luc (B) and treated for 8 h with vehicle, 100 nM PGF2alpha, 100 nM PGF2alpha in the absence/presence of AL8810, YM254890, U73122, 4C3MQ, RO-318220, EGTA, Inca-6 or CsA and NFAT cis-acting enhancer DNA activation was measured by luciferase reporter assay. Ishikawa FPS cells were transiently transfected with the pAP1-luc (C) or pNFAT-luc (D) reporter plasmid and either incubated with transretinoic acid or co-transfected with an empty vector or dn c-Jun cDNA construct. Ishikawa FPS cells were transfected with the - 162/+ 44 or - 1400/+ 44 (E) CXCL8 luciferase reporter cDNA and co-transfected with empty vector or dn c-Jun cDNA. Cells were treated with vehicle or 100 nM PGF2alpha for 8 h. (b is significantly different from a and c is significantly different from a and b; P < 0.01). Data are represented as mean +/- SEM.
###end p 126
###begin p 127
###xml 126 132 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 458 464 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 520 526 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 538 544 526 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 975 981 959 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
RCAN1-4 overexpression negatively regulates CXCL8 in Ishikawa FPS cells. (A) FPS cells were treated with vehicle or 100 nM PGF2alpha for 8 h. The various RCAN isoforms (RCAN1-1, 1-2, 1-4) were detected by PCR using specific primers and normalised to expression of GAPDH. (B) RCAN1-4 mRNA expression in Ishikawa FPS cells as measured by real-time quantitative RT-PCR analysis following treatment of cells for 0, 2, 4, 6, 8, 12, 24, 48 and 72 h with 100 nM PGF2alpha. (C) FPS cells treated for 8 h with vehicle, 100 nM PGF2alpha, 100 nM PGF2alpha in the absence/presence of AL8810, YM254890, U73122, 4C3MQ, RO-318220, EGTA, Inca-6 or CsA and RCAN1-4 expression was determined by quantitative RT-PCR analysis. Ishikawa FPS cells were transiently transfected with the full length - 1400/+ 44 CXCL8 promoter (D) or left untransfected (E and F) and infected with either scrambled control adenovirus or RCAN1-4 adenovirus for 24 h. Cells were then treated with vehicle or 100 nM PGF2alpha for 8 h and CXCL8 promoter (D), mRNA (E) and protein (F) expression was determined by luciferase reporter assay, quantitative RT-PCR analysis or ELISA respectively (b is significantly different from a and c is significantly different from a and b; P < 0.01). Data are represented as mean +/- SEM.
###end p 127
###begin p 128
###xml 578 584 575 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 683 689 676 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1035 1041 1024 1026 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 1394 1395 1379 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
RCAN1-4 is a negative regulator of CXCL8 mRNA in FPS cells. (A) Ishikawa FPS cells were infected with 1 molecule of infection (MOI) per cell of scrambled lentivirus control or RCAN1-4 ShRNA lentivirus (1 or 2 MOI) as described in the Methods. Immunoblotting was performed using standard techniques using a specific RCAN antibody.beta-Actin was used in parallel as a loading control. We confirmed that RCAN1-4 was a negative regulator of CXCL8 expression using a lentiviral ShRNA targeted against RCAN1-4. Infection of FPS cells with the RCAN1-4 lentiviral ShRNA enhanced the PGF2alpha-mediated induction of CXCL8 mRNA (B) and protein (C) expression in FPS cells treated with 1 nM PGF2alpha for 8 h compared with control scrambled lentivirus. (D) Ishikawa FPS cells were transiently transfected with the pAP1-luc or pNFAT-luc cDNA containing the AP1 or NFAT cis-acting enhancer elements respectively and infected with either scrambled control adenovirus or RCAN1-4 adenovirus for 24 h. Cells were then treated with vehicle or 100 nM PGF2alpha for 8 h and AP1 and NFAT luciferase activity was measured by luciferase reporter assay. (E) Cell proliferation was determined in Ishikawa FPS cells treated with vehicle or recombinant CXCL8 for 24, 48 and 72 h in the absence/presence of the CXCR2 antagonist SB225002. (b is significantly different from a and c is significantly different from a and b; P < 0.01). Data are represented as mean +/- SEM.
###end p 128
###begin p 129
###xml 127 128 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 673 674 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 743 749 743 745 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 763 769 759 761 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 925 931 917 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 979 980 967 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
CXCL8 expression and localization in endometrial tissues. (A) Relative mRNA expression of CXCL8 in endometrial adenocarcinoma (n = 30; 10 of each poorly moderately and well differentiated adenocarcinoma) and normal endometrium (n = 30; 10 of each proliferative, early secretory and mid secretory endometrium) as determined by quantitative RT-PCR analysis. (B) Immunolocalisation of CXCL8 in an example of Well differentiated endometrial adenocarcinoma as determined by immunohistochemistry showing positive immunoreactivity (brown staining) in the glandular (G) and stromal (S) compartment. (C) CXCL8 mRNA and (D) protein expression in endometrial adenocarcinoma explants (n = 3) following treatment of tissue for 24 h with vehicle, 100 nM PGF2alpha or 100 nM PGF2alpha and AL8810. (E) Infection of endometrial adenocarcinoma explants with scrambled (Scr) or RCAN1-4 adenovirus prior to stimulation with vehicle or 100 nM PGF2alpha for 24 h (b is significantly different from a; P < 0.001). Data are represented as mean +/- SEM. Scale bar = 50 mum.
###end p 129
###begin p 130
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 146 153 146 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nu</sup>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 285 286 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 707 708 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
CXCL8 enhances proliferation of Ishikawa FPS cells in vivo. (A, B, C) The effects of CXCL8 neutralising antibody on epithelial cell proliferation in vivo. The CD1-Foxn1nu mice were engrafted with Ishikawa FPS cells and treated with CXCL8 neutralising antibody (n = 10) or IgG control (n = 10). The incorporation of BrdU (A) in the epithelial compartment and number of epithelial cells as determined by cytokeratin 18 positive immunoreactivity (B) per tissue section were determined by immunohistochemistry (brown staining) and quantified (C) by standard stereology techniques. (b is significantly different from a; c is significantly different from a, b and d, d is significantly different from a, b and c; P < 0.001). Data are represented as mean +/- SEM. Scale bar = 50 mum.
###end p 130
###begin p 131
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">Table 1</xref>
###xml 161 167 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
Summary. A schematic summary of our findings which includes the points of inhibition of the various inhibitors outlined in Table 1 on the signalling cascade. PGF2alpha-FP receptor activation in endometrial adenocarcinoma cells promotes the induction of RCAN1-4 and CXCL8 via the Gq-PLC-PKC-calcium-calcineurin-NFAT cascade. The expression of RCAN1-4 and CXCL8 are reciprocal and RCAN1-4 expression precedes CXCL8 expression by 4-8 h. We found that RCAN1-4 acts as a negative regulator of the calcineurin pathway to prevent over induction of CXCL8, such that when levels of RCAN1-4 are high, CXCL8 levels are suppressed. When RCAN1-4 levels wane over time, CXCL8 expression is induced to maximal to promote tumour cell proliferation via the CXCR2 receptor on epithelial cells.
###end p 131
###begin p 132
List of reagents summarising the targets of each compound.
###end p 132

